Skip to main content

Table 2 Baseline demographic and clinical characteristics of Medicaid beneficiaries newly prescribed HIV treatment

From: Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries

Baseline demographics and clinical characteristicsAdherence assessment populationPersistence assessment population
Overall patients (N = 1744)STRs (N = 1290)MTRs (N = 454)Overall patients (N = 2409)STRs (N = 1782)MTRs (N = 627)
N (%)N (%)N (%)N (%)N (%)N (%)
Mean age (mean ± SD)41.0 ± 12.940.0 ± 13.342.0 ± 11.840.1 ± 13.140.0 ± 13.541.0 ± 12.0
Age group (years)
 18–34631 (36.2%)493 (38.2%)138 (30.4%)918 (38.1%)714 (40.1%)204 (32.5%)
 35–49614 (35.2%)432 (33.5%)182 (40.1%)805 (33.4%)559 (31.4%)246 (39.2%)
 50–64468 (26.8%)338 (26.2%)130 (26.8%)646 (26.8%)473 (26.5%)173 (27.6%)
 ≥ 6531 (1.8%)27 (2.1%)4 (0.9%)40 (1.7%)36 (2.0%)4 (0.6%)
Gender
 Male986 (56.5%)741 (57.4%)245 (54.0%)1353 (56.2%)1026 (57.6%)327 (52.2%)
 Female758 (43.5%)549 (42.6%)209 (46.0%)1056 (43.8%)756 (42.4%)300 (47.8%)
Race
 White350 (20.1%)270 (20.9%)80 (17.6%)472 (19.6%)358 (20.1%)114 (18.2%)
 Black1064 (61.0%)779 (60.4%)285 (62.8%)1460 (60.6%)1078 (60.5%)382 (60.9%)
 Hispanic26 (1.5%)18 (1.4%)8 (1.8%)37 (1.6%)26 (1.5%)11 (1.8%)
 Other304 (17.4%)223 (17.3%)81 (17.8%)440 (18.3%)320 (18.0%)120 (19.1%)
Insurance type
 HMO445 (25.5%)342 (26.5%)103 (22.7%)635 (26.4%)480 (26.9%)155 (24.7%)
 COMP1298 (74.4%)948 (73.5%)350 (77.1%)1773 (73.6%)1302 (73.1%)471 (75.1%)
Pre-index medication use
 Antihypertensive439 (25.2%)329 (25.5%)110 (24.2%)567 (23.5%)425 (23.8%)142 (22.6%)
 Antidiabetics106 (6.1%)83 (6.4%)23 (5.1%)143 (5.9%)107 (6.0%)36 (5.7%)
 Metformin67 (3.8%)54 (4.2%)13 (2.9%)86 (3.6%)68 (3.8%)18 (2.9%)
 Metformin-combination4 (0.2%)3 (0.2%)1 (0.2%)5 (0.2%)3 (0.2%)2 (0.3%)
 Non-insulin therapy78 (4.5%)63 (4.9%)15 (3.3%)101 (4.2%)80 (4.5%)21 (3.3%)
 Insulin43 (2.5%)32 (2.5%)11 (2.4%)59 (2.5%)43 (2.4%)16 (2.6%)
 Anticoagulants102 (5.9%)77 (6.0%)25 (5.5%)133 (5.5%)101 (5.7%)32 (5.1%)
 Antiarrhythmic drugs1 (0.1%)1 (0.1%)0 (0.0%)1 (0.04%)1 (0.1%)0 (0.0%)
 Lipid-lowering therapy150 (8.6%)111 (8.6%)39 (8.6%)193 (8.0%)143 (8.0%)50 (8.0%)
 Statin148 (8.5%)110 (8.5%)38 (8.4%)191 (7.9%)142 (8.0%)49 (7.8%)
 Ezetimibe3 (0.2%)2 (0.2%)1 (0.2%)3 (0.1%)2 (0.1%)1 (0.2%)
 Statin/ezetimibe1 (0.1%)1 (0.1%)0 (0.0%)1 (0.04%)1 (0.1%)0 (0.0%)
 PCSK9 0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (0.0%)
 Antibiotics759 (43.5%)584 (45.3%)175 (38.5%)1068 (44.3%)810 (45.5%)258 (41.1%)
 Respiratory drugsa958 (54.9%)735 (57.0%)223 (49.1%)1353 (56.2%)1029 (57.7%)324 (51.7%)
 Number of unique medications on index date besides ART (mean ± SD)1.0 ± 1.90.9 ± 1.81.3 ± 2.11.0 ± 2.01.0 ± 1.91.3 ± 2.3
 Deyo-modified CCI score (mean ± SD)4.2 ± 3.44.1 ± 3.44.4 ± 3.43.4 ± 3.53.4 ± 3.53.6 ± 3.5
Baseline clinical comorbidities
 Central nervous system toxicity714 (40.9%)530 (41.1%)184 (40.5%)811 (33.7%)598 (33.6%)213 (34.0%)
 Gastrointestinal symptoms74 (4.2%)55 (4.3%)19 (4.2%)81 (3.7%)60 (3.4%)21 (3.3%)
 Mental disorders986 (56.5%)732 (56.7%)254 (55.9%)1134 (47.1%)835 (46.9%)299 (47.7%)
 AIDS-defining condition118 (6.8%)79 (6.1%)39 (8.6%)124 (5.2%)82 (4.6%)42 (6.7%)
 Substance abuse724 (41.5%)522 (40.5%)202 (44.5%)827 (34.3%)591 (33.2%)236 (37.6%)
 Jaundice9 (0.5%)6 (0.5%)3 (0.7%)9 (0.4%)6 (0.3%)3 (0.5%)
 Dyslipidemia251 (14.4%)193 (15.0%)58 (12.8%)270 (11.2%)209 (11.7%)61 (9.7%)
 Diabetes149 (8.5%)115 (8.9%)34 (7.5%)172 (7.1%)131 (7.4%)41 (6.5%)
 Chronic kidney disease58 (3.3%)42 (3.3%)16 (3.5%)62 (2.6%)46 (2.6%)16 (2.6%)
 Cardiovascular disease562 (32.2%)415 (32.2%)147 (32.4%)628 (26.1%)465 (26.1%)163 (26.0%)
 Myocardial infarction12 (0.7%)8 (0.6%)4 (0.9%)12 (0.5%)8 (0.4%)4 (0.6%)
  1. STR single-tablet regimen, MTR single-tablet regimen, SD standard deviation, CCI Charlson comorbidity index, HMO health maintenance organization, COMP comprehensive (patients were not incentivized to use a particular list of providers for non-emergency care, and coverage was handled by only one policy)
  2. aInclude drugs for lower and upper respiratory infections